Key facts
- It has raised $85.8M; the latest was Later Stage VC ($7.4M) in Jun 2025.
- Notable investors include Sequoia Capital, Hongshan Capital Group, Connecticut Innovations, Samsara BioCapital, Logos Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Simcha Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Simcha Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Simcha Therapeutics
Developer of cytokine immunotherapies intended to trigger the immune system to fight disease, particularly cancers. The company's decoy-resistant immunotherapies use directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system, enabling patients to fight diseases with a better immune system.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2018
- Employees
- 14
- Website
- simchatx.com/
- Ownership
- Privately Held (backing)
Simcha Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Simcha Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Simcha Therapeutics in its N-PORT filings yet. We sweep new filings monthly.